GMP PROTEIN (E. COLI) CONTRACT MANUFACTURING MARKET ANALYSIS

GMP Protein (E. coli) Contract Manufacturing Market, by Product Type (Cytokines, Growth Factors, Enzymes [DNA polymerase, Protease, Trypsin, Nuclease {Benzonase, Cas9 Nucleases, and Others}, IVT Enzymes, and Others] Hormones, Antigens, and Others), by Application (Gene Therapy and Cell Therapy), by Method (In-Vivo and Ex-Vivo), by End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI5433
Pages :603
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Global GMP Protein (E. coli) Contract Manufacturing Market - Key Players

Major players operating in the global GMP protein (E. coli) contract manufacturing market include Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne , Northway Biotech , Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma , FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus , F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.